LFNG Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| FC, IHC-P, WB, E |
---|---|
Primary Accession | Q8NES3 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 41773 Da |
Antigen Region | 86-114 aa |
Gene ID | 3955 |
---|---|
Other Names | Beta-1, 3-N-acetylglucosaminyltransferase lunatic fringe, O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase, LFNG |
Target/Specificity | This LFNG antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 86-114 amino acids from the Central region of human LFNG. |
Dilution | WB~~1:1000 IHC-P~~1:50~100 FC~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | LFNG Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | LFNG (HGNC:6560) |
---|---|
Function | Glycosyltransferase that initiates the elongation of O-linked fucose residues attached to EGF-like repeats in the extracellular domain of Notch molecules. Modulates NOTCH1 activity by modifying O- fucose residues at specific EGF-like domains resulting in inhibition of NOTCH1 activation by JAG1 and enhancement of NOTCH1 activation by DLL1 via an increase in its binding to DLL1 (By similarity). Decreases the binding of JAG1 to NOTCH2 but not that of DLL1 (PubMed:11346656). Essential mediator of somite segmentation and patterning (By similarity). |
Cellular Location | Golgi apparatus {ECO:0000250|UniProtKB:O09010}. Golgi apparatus membrane; Single-pass type II membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
LFNG belongs to evolutionarily conserved glycosyltransferases that act in the Notch signaling pathway to define boundaries during embryonic development. While their genomic structure is distinct from other glycosyltransferases, fringe proteins have a fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity that leads to elongation of O-linked fucose residues on Notch, which alters Notch signaling. This protein is predicted to be a single-pass type II Golgi membrane protein but it may also be secreted and proteolytically processed like the related proteins in mouse and Drosophila (PMID: 9187150).
References
Dunwoodie, S.L. Biochim. Biophys. Acta 1792(2):100-111(2009)
Reedijk, M., et al. Int. J. Oncol. 33(6):1223-1229(2008)
Sparrow, D.B., et al. Am. J. Hum. Genet. 78(1):28-37(2006)
Cole, S.E., et al. Dev. Cell 3(1):75-84(2002)
Moran, J.L., et al. Mamm. Genome 10(6):535-541(1999)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.